drugset / Trial / NCT02762591
Expanded Access of Pimavanserin for Patients With PD Psychosis
Summary
The purpose of this program is to provide patients with PDP access to pimavanserin until the product receives marketing approval from the FDA and is commercially available.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Pimavanserin | Small molecule | 40 mg | Oral |